In A Nutshell A handheld breath sensor read eight chemicals and flagged lung cancer risk in a 67-person study. Accuracy was 85.71% using the device alone and 92.86% when paired with GC–MS in analysis.

BioMark Diagnostics ( ($TSE:BUX) ) has provided an announcement. BioMark Diagnostics Inc. and its research partners have been honored with the ...

Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform Vancouver, British Columbia–(Newsfile Corp. – December ...

Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...

Researchers have unveiled new AI tools, from smartphone cough analysis to child-friendly screening systems, which could ...

The equipment looks futuristic. The demand is widespread. Inside the Thoracic Oncology Mobile Experience Truck parked outside Portsmouth Regional Hospital on Sept. 25, clinicians, research associates ...

Detailed price information for Biomark Diagnostics Inc (BUX-CN) from The Globe and Mail including charting and trades.

Complex digital images of tissue samples that can take an experienced pathologist up to 20 minutes to annotate could be ...

This important study describes a deep learning framework that analyzes single-cell RNA data to identify a tumor-agnostic gene signature associated with brain metastases. The identified signature ...

Diffuse large B-cell lymphoma (DLBCL) is an aggressive blood cancer that kills most untreated patients within one year. Standard CHOP chemotherapy improves five-year survival to 70%—still a ...